Rebecca Kate Miller-Kuhlmann, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Miller-Kuhlmann’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A133352 · Current
Licensed to practise in California · since 2014 · expires 2028-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$36,382
Medicare paid this office $36,382 for 102 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 35 | $5,880 | $125 |
| Face injection for nerve paralysis | 15 | $5,515 | $138 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 20 | $4,575 | $97 |
| Long return visit (40+ min) | 18 | $3,460 | $165 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 18 | $2,297 | $74 |
See all 12 services
| Long return visit (40+ min) | 35 | $5,880 | $125 |
| Face injection for nerve paralysis | 15 | $5,515 | $138 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 20 | $4,575 | $97 |
| Long return visit (40+ min) | 18 | $3,460 | $165 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 18 | $2,297 | $74 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, each additional extremity | 12 | $1,966 | $68 |
| Return visit (30+ min) | 15 | $1,779 | $111 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 15 | $1,655 | $57 |
| Return visit (30+ min) | 14 | $1,580 | $75 |
| Muscle electrical test | 37 | $1,555 | $17 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 26 | $434 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $225 | $15 |
Who their Medicare patients are
102 Original Medicare patients in 2024. Average age 71 · Under 65 22% · 85 and older 18% · Women 54% · Also on Medicaid 30% · Health risk score 1.59. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 64% · Depression 25% · Stroke 25% · Diabetes 24% · Coronary heart disease 18% · Chronic kidney disease 18% · Dementia 16% · Cancer 14%.
The office billed $226,190, Medicare allowed $48,541 and paid $36,382; for 473 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 102 | 473 | 71 | 1.59 | $226,190 | $36,382 |
| 2023 | 109 | 433 | 71 | 1.51 | $231,619 | $35,504 |
| 2022 | 117 | 347 | 70 | 1.57 | $176,824 | $25,518 |
| 2021 | 154 | 524 | 71 | 1.69 | $261,498 | $43,358 |
| 2020 | 171 | 446 | 71 | 1.70 | $206,233 | $32,848 |
| 2019 | 291 | 772 | 71 | 1.55 | $476,058 | $60,465 |
| 2018 | 129 | 186 | 73 | 1.45 | $79,867 | $19,369 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 44 | $8,529 | $122 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 18 | $5,151 | $103 |
| Return visit (30+ min) | 41 | $4,741 | $85 |
| Face injection for nerve paralysis | 11 | $3,366 | $140 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 13 | $2,583 | $63 |
| Muscle electrical test | 27 | $1,401 | $18 |
2022: 6 services
| Long return visit (40+ min) | 39 | $5,504 | $108 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 22 | $3,437 | $86 |
| Return visit (30+ min) | 37 | $3,273 | $76 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 18 | $1,978 | $52 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 13 | $1,663 | $83 |
| Muscle electrical test | 36 | $1,084 | $17 |
2021: 7 services
| Long return visit (40+ min) | 59 | $10,735 | $114 |
| Return visit (30+ min) | 54 | $5,903 | $86 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 23 | $5,676 | $95 |
| Face injection for nerve paralysis | 11 | $3,942 | $141 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 21 | $3,769 | $63 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 15 | $2,681 | $89 |
| Muscle electrical test | 38 | $1,578 | $19 |
2020: 7 services
| Long return visit (40+ min) | 54 | $7,348 | $99 |
| Return visit (30+ min) | 65 | $4,606 | $63 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 21 | $4,465 | $95 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 17 | $3,160 | $63 |
| New patient visit (60+ min) | 14 | $1,724 | $123 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 11 | $1,330 | $83 |
| Muscle electrical test | 31 | $1,121 | $18 |
2019: 12 services
| Long return visit (40+ min) | 118 | $14,305 | $87 |
| New patient visit (60+ min) | 56 | $7,746 | $138 |
| Return visit (30+ min) | 73 | $6,180 | $66 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 27 | $5,814 | $102 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 25 | $4,778 | $62 |
| Face injection for nerve paralysis | 12 | $3,495 | $134 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 19 | $3,393 | $94 |
| New patient visit (45+ min) | 24 | $2,643 | $110 |
| Muscle electrical test | 45 | $1,756 | $18 |
| Nerve test | 12 | $1,489 | $124 |
| Muscle electrical test | 23 | $1,156 | $43 |
| Muscle electrical test | 21 | $453 | $17 |
2018: 5 services
| New patient visit (60+ min) | 43 | $5,461 | $127 |
| New patient visit (60+ min) | 27 | $3,777 | $140 |
| Long return visit (40+ min) | 27 | $3,093 | $100 |
| Long return visit (40+ min) | 26 | $2,594 | $100 |
| Return visit (30+ min) | 14 | $958 | $68 |
Drugs they prescribed that Part D paid
$76,585
Pharmacies billed $76,585 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
398 generic and 56 brand-name prescriptions · $76,585 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 16 | $27,544 | $1,721 |
| Neupro | None | 13 | $12,247 | $942 |
| Carbidopa-Levodopa | None | 79 | $5,359 | $68 |
| Entacapone | None | 19 | $3,821 | $201 |
| Carbidopa-Levodopa Er | None | 32 | $2,508 | $78 |
See all 13 drugs
| Rytary | Parkinson's | 16 | $27,544 | $1,721 |
| Neupro | None | 13 | $12,247 | $942 |
| Carbidopa-Levodopa | None | 79 | $5,359 | $68 |
| Entacapone | None | 19 | $3,821 | $201 |
| Carbidopa-Levodopa Er | None | 32 | $2,508 | $78 |
| Amantadine | None | 11 | $886 | $81 |
| Gabapentin | None | 31 | $679 | $22 |
| Propranolol Hcl Er | None | 11 | $594 | $54 |
| Pregabalin | None | 16 | $276 | $17 |
| Clonazepam | None | 32 | $230 | $7 |
| Donepezil | None | 13 | $228 | $18 |
| Lamotrigine | None | 12 | $59 | $5 |
| Diazepam | None | 15 | $34 | $2 |
Year by year
| 2024 | 454 | 66 | None | 12% | $76,585 |
| 2023 | 413 | 68 | 0% (0) | 8% | $82,109 |
| 2022 | 520 | 72 | 0% (0) | 11% | $95,874 |
| 2021 | 641 | 82 | None | 14% | $130,039 |
| 2020 | 578 | 85 | 0% (0) | 9% | $85,006 |
| 2019 | 539 | 119 | None | 8% | $70,976 |
| 2018 | 147 | 48 | 0% (0) | None | $6,355 |
| 2017 | 16 | 11 | 0% (0) | None | $2,298 |
| 2016 | 13 | None | 0% (0) | 0% | $836 |
| 2015 | 14 | None | 0% (0) | None | $2,883 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Neupro | 11 | $9,963 | $906 |
| Carbidopa-Levodopa | 84 | $8,622 | $103 |
| Entacapone | 11 | $6,245 | $568 |
| Carbidopa-Levodopa Er | 53 | $3,915 | $74 |
| Gabapentin | 30 | $1,300 | $43 |
| Amantadine | 14 | $1,089 | $78 |
| Atropine Sulfate | 21 | $476 | $23 |
| Clonazepam | 16 | $412 | $26 |
| Donepezil | 16 | $361 | $23 |
| Pregabalin | 16 | $259 | $16 |
2022: 11 drugs
| Neupro | 16 | $16,154 | $1,010 |
| Entacapone | 25 | $9,461 | $378 |
| Carbidopa-Levodopa | 121 | $8,678 | $72 |
| Carbidopa-Levodopa Er | 50 | $4,647 | $93 |
| Amantadine | 27 | $2,341 | $87 |
| Gabapentin | 33 | $1,357 | $41 |
| Midodrine | 11 | $453 | $41 |
| Pregabalin | 17 | $396 | $23 |
| Escitalopram | 16 | $321 | $20 |
| Donepezil | 16 | $184 | $11 |
| Clonazepam | 22 | $148 | $7 |
2021: 18 drugs
| Neupro | None | 32 | $31,065 | $971 |
| Rytary | Parkinson's | 12 | $20,316 | $1,693 |
| Carbidopa-Levodopa | None | 148 | $12,459 | $84 |
| Entacapone | None | 22 | $8,654 | $393 |
| Carbidopa-Levodopa Er | None | 49 | $5,105 | $104 |
| Amantadine | None | 33 | $4,698 | $142 |
| Rivastigmine | None | 12 | $3,895 | $325 |
| Propranolol Hcl Er | None | 13 | $2,421 | $186 |
| Duloxetine | None | 22 | $2,142 | $97 |
| Gabapentin | None | 38 | $1,419 | $37 |
| Clonazepam | None | 38 | $1,018 | $27 |
| Propranolol | None | 13 | $756 | $58 |
| Pregabalin | None | 17 | $575 | $34 |
| Ropinirole | None | 17 | $510 | $30 |
| Donepezil | None | 25 | $498 | $20 |
| Escitalopram | None | 18 | $299 | $17 |
| Atorvastatin | None | 12 | $135 | $11 |
| Lamotrigine | None | 12 | $97 | $8 |
2020: 14 drugs
| Neupro | 19 | $21,031 | $1,107 |
| Carbidopa-Levodopa | 149 | $10,386 | $70 |
| Entacapone | 17 | $6,176 | $363 |
| Amantadine | 46 | $5,911 | $128 |
| Carbidopa-Levodopa Er | 41 | $4,815 | $117 |
| Rivastigmine | 16 | $3,709 | $232 |
| Propranolol Hcl Er | 14 | $1,858 | $133 |
| Clonazepam | 37 | $1,275 | $34 |
| Gabapentin | 48 | $1,205 | $25 |
| Propranolol | 15 | $957 | $64 |
| Ropinirole | 19 | $652 | $34 |
| Donepezil | 18 | $296 | $16 |
| Atorvastatin | 13 | $188 | $14 |
| Escitalopram | 15 | $141 | $9 |
2019: 11 drugs
| Carbidopa-Levodopa | 145 | $6,435 | $44 |
| Amantadine | 49 | $5,178 | $106 |
| Rivastigmine | 12 | $4,764 | $397 |
| Entacapone | 16 | $3,843 | $240 |
| Carbidopa-Levodopa Er | 39 | $2,883 | $74 |
| Duloxetine | 25 | $730 | $29 |
| Gabapentin | 41 | $664 | $16 |
| Donepezil | 41 | $551 | $13 |
| Escitalopram | 19 | $527 | $28 |
| Propranolol Hcl Er | 15 | $464 | $31 |
| Clonazepam | 13 | $293 | $23 |
2018: 4 drugs
| Carbidopa-Levodopa | 23 | $749 | $33 |
| Duloxetine | 17 | $610 | $36 |
| Donepezil | 21 | $582 | $28 |
| Gabapentin | 29 | $457 | $16 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417290867
- Licence
- CA A133352California A133352: Current · expires 2028-09-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 204R00000X (204R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-04
- NPI last updated
- 2023-11-09
- NPI record certified
- 2023-11-09
This is when the NPI record was last certified, not a medical board exam.